Prospective Grant of a Start-up Exclusive Commercial License Agreement: Development of MHC Class II Restricted T Cell Epitopes From the Cancer Antigen, NY ESO-1, for the Treatment of Human Cancers, 59797-59798 [2015-24982]
Download as PDF
<![CDATA[
Federal Register / Vol. 80, No. 191 / Friday, October 2, 2015 / Notices
signal that indicates the blade location
with respect to the base plate.
Advantageously, this allows for a stage
coupled pedestal to be moved
accurately from an imaging location on
the beam axis to a cutting location off
the beam axis.
The prospective start-up exclusive
license may be granted unless within
thirty (30) days from the date of this
published notice, the NIH receives
written evidence and argument that
establishes that the grant of the license
would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR part 404.
Complete applications for a license in
the field of use filed in response to this
notice will be treated as objections to
the grant of the contemplated start-up
exclusive license. Comments and
objections submitted to this notice will
not be made available for public
inspection and, to the extent permitted
by law, will not be released under the
Freedom of Information Act, 5 U.S.C.
552.
Dated: September 28, 2015.
Richard U. Rodriguez,
Acting Director, Office of Technology
Transfer, National Institutes of Health.
[FR Doc. 2015–24994 Filed 10–1–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of a Start-up
Exclusive Commercial License
Agreement: Development of MHC
Class II Restricted T Cell Epitopes
From the Cancer Antigen, NY ESO–1,
for the Treatment of Human Cancers
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
This is notice, in accordance
with 35 U.S.C. 209 and 37 CFR part
404.7, that the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of an start-up exclusive
commercial license to Immunova
Therapeutics, Inc., which is located in
Houston, Texas, to practice the
inventions embodied in the following
patent applications and applications
claiming priority to these applications:
mstockstill on DSK4VPTVN1PROD with NOTICES
SUMMARY:
E–090–2000
1. U.S. Provisional Patent Application No.
61/179,004 filed January 28, 2000
entitled ‘‘MHC Class II Restricted T Cell
Epitopes from the Cancer Antigen, NY
ESO–1’’ (HHS Ref No. E–090–2000/0–
VerDate Sep<11>2014
20:43 Oct 01, 2015
Jkt 238001
US–01);
2. U.S. Provisional Patent Application No.
60/237,107 filed September 29, 2000
entitled ‘‘HLA–DP Restricted CD4+ T
Cell Epitopes from the Cancer Antigen,
NY ESO–1’’ (HHS Ref No. E–227–2000/
0–US–01 was combined with E–090–
2000/0–US–01 at the PCT stage, creating
the E–090–2000/1 technology family and
associated applications);
3. PCT Application No. PCT/US01/02765
filed January 26, 2001 entitled ‘‘MHC
Class II Restricted T Cell Epitopes from
the Cancer Antigen, NY ESO–1’’ (HHS
Ref No. E–090–2000/1–PCT–01);
4. Canadian Patent No. 2398743 issued June
23, 2015 entitled ‘‘MHC Class II
Restricted T Cell Epitopes from the
Cancer Antigen, NY ESO–1’’ (HHS Ref
No. E–090–2000/1–CA–02);
5. Australian Patent No. 785151 issued
January 18, 2007 entitled ‘‘MHC Class II
Restricted T Cell Epitopes from the
Cancer Antigen, NY ESO–1’’ (HHS Ref
No. E–090–2000/1–AU–03);
6. Japanese Patent No. 5588363 issued
August 1, 2014 entitled ‘‘MHC Class II
Restricted T Cell Epitopes from the
Cancer Antigen, NY ESO–1’’ (HHS Ref
No. E–090–2000/1–JP–12);
7. U.S. Patent No. 7,619,057 issued
November 17, 2009 entitled ‘‘MHC Class
II Restricted T Cell Epitopes from the
Cancer Antigen, NY ESO–1’’ (HHS Ref
No. E–090–2000/1–US–06);
8. U.S. Patent No. 8,754,046 issued June 17,
2014 entitled ‘‘MHC Class II Restricted T
Cell Epitopes from the Cancer Antigen,
NY ESO–1’’ (HHS Ref No. E–090–2000/
1–US–07);
9. U.S. Patent Application No. 12/568,134
filed September 28, 2009 entitled ‘‘MHC
Class II Restricted T Cell Epitopes from
the Cancer Antigen, NY ESO–1’’ (HHS
Ref No. E–090–2000/1–US–013);
10. European Patent Application No.
10010354.8 filed January 26, 2001
entitled ‘‘MHC Class II Restricted T Cell
Epitopes from the Cancer Antigen, NY
ESO–1’’ (HHS Ref No. E–090–2000/1–
EP–10);
The patent rights in these inventions
have been assigned to the Government
of the United States of America. The
prospective start-up exclusive
commercial license territory may be
worldwide and the field of use may be
limited to the use of the Licensed Patent
Rights to develop, manufacture,
distribute, sell and use NY–ESO–1
based vaccines and cell therapy
products for the treatment of NY–ESO–
1-positive cancers.
DATES: Only written comments and/or
applications for a license which are
received by the NIH Office of
Technology Transfer on or before
October 19, 2015 will be considered.
ADDRESSES: Requests for copies of the
patent applications, inquiries,
comments, and other materials relating
to the contemplated exclusive
evaluation option license should be
PO 00000
Frm 00078
Fmt 4703
Sfmt 4703
59797
directed to: Sabarni K. Chatterjee, Ph.D.,
M.B.A., Senior Licensing and Patenting
Manager, NCI Technology Transfer
Center, 9609 Medical Center Drive, RM
1E530 MSC 9702, Bethesda, MD 20892–
9702 (for business mail), Rockville, MD
20850–9702; Telephone: (240) 276–
5530; Facsimile: (240) 276–5504; Email:
chatterjeesa@mail.nih.gov.
SUPPLEMENTARY INFORMATION: NY–ESO–
1 is a known tumor antigen which is
expressed on a broad range of tumor
types, including melanoma, breast,
bladder, ovarian, prostate, head and
neck cancers, neuroblastoma, and small
cell lung cancer. The above-referenced
inventions embody the identification of
a number of novel immunogenic
peptide epitopes, and analogs thereof,
which are derived from the NY–ESO–1
tumor antigen. Specifically, this
technology describes novel MHC Class
II restricted epitopes of NY–ESO–1
which are recognized by CD4+ T cells.
It also embodies the identification of
two additional immunogenic peptide
epitopes of NY–ESO–1. The latter two
epitopes are presented by HLA–DP4, a
prevalent MHC Class II allele present in
43–70% of Caucasians. The inventors
also determined that the DP allele is
highly associated with the NY–ESO–1
antibody production. In addition, one of
these epitopes has dual HLA A2 and
DP4 specificity, thereby it has the
potential to generate both CD4+ and
CD8+ tumor specific T cells. These
epitopes may be of great value as
prophylactic and/or therapeutic cancer
vaccines or cell therapy products for use
against a number of common cancers.
The prospective start-up exclusive
commercial license is being considered
under the small business initiative
launched on October 1, 2011 and will
comply with the terms and conditions
of 35 U.S.C. 209 and 37 CFR part 404.7.
The prospective start-up exclusive
commercial license may be granted
unless within fifteen (15) days from the
date of this published notice, the NIH
receives written evidence and argument
that establishes that the grant of the
license would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR part 404.7.
Any additional, properly filed, and
complete applications for a license in
the field of use filed in response to this
notice will be treated as objections to
the grant of the contemplated exclusive
commercial license. Comments and
objections submitted to this notice will
not be made available for public
inspection and, to the extent permitted
by law, will not be released under the
Freedom of Information Act, 5 U.S.C.
552.
E:\FR\FM\02OCN1.SGM
02OCN1
59798
Federal Register / Vol. 80, No. 191 / Friday, October 2, 2015 / Notices
Dated: September 28, 2015.
Richard U. Rodriguez,
Acting Director, Office of Technology
Transfer, National Institutes of Health.
published under the publication rules of
either the United States Patent and
Trademark Office or the World
Intellectual Property Organization.
[FR Doc. 2015–24982 Filed 10–1–15; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive
License: Analytical Instruments
Utilizing Condensation Particle
Counters for the Detection and
Analysis of Small Aerosol Particles
Public Health Service, National
Institutes of Health, HHS.
ACTION: Notice.
AGENCY:
This is notice, in accordance
with 35 U.S.C. 209 and 37 CFR part 404,
that the Public Health Service,
Department of Health and Human
Services, is contemplating the grant of
an exclusive license to Kanomax Japan,
Inc. having a principal place of business
in Osaka, Japan, to practice the
inventions embodied in U.S. Provisional
Patent Application No. 62/026,559, filed
on 18 July 2014, entitled ‘‘Aerosol
Particle Growth Systems for Personal
Sampling Applications Using Polymer
Electrolyte Membranes’’ [HHS Reference
No. E–026–2014/0–US–01]. The patent
rights in these inventions have been
assigned to the United States of
America. The territory of the
prospective exclusive patent license
may be worldwide, and the field of use
may be limited to ‘‘Analytical
instruments comprising condensation
particle counters (CPCs) for the
sampling, detection, counting and
analysis of ultrafine and nano-sized
aerosol particles.’’
DATES: Only written comments and/or
applications for a license that are
received by the NIH Office of
Technology Transfer on or before
November 2, 2015 will be considered.
ADDRESSES: Requests for a copy of the
patent application, inquiries, comments
and other materials relating to the
contemplated license should be directed
to: Tara L. Kirby, Ph.D., Chief, CDC
Unit, Office of Technology Transfer,
National Institutes of Health, 6011
Executive Boulevard, Suite 325,
Rockville, MD 20852–3804; Telephone:
(301) 435–4426; Facsimile: (301) 402–
0220; Email: tarak@mail.nih.gov. A
signed confidential disclosure
agreement may be required to receive
copies of the patent application
assuming it has not already been
mstockstill on DSK4VPTVN1PROD with NOTICES
VerDate Sep<11>2014
20:43 Oct 01, 2015
Jkt 238001
Hazardous
airborne particles pose a risk for health
and safety in a variety of environments
and thus detection of these small
particles is essential. Current particle
magnification systems are bulky and
require a lot of power for operation,
making them unsuitable to easily detect
and analyze small particles in mobile
and personal settings.
The CDC has developed space-saving
miniature instrumentation and methods
for the direct sampling and analysis of
small particles (diameter <300–400 nm).
The systems can effectively sample air
at a rate of a few liters per minute and
concentrate the particulate matter into
microliter or milliliter liquid samples.
The novel system uses proton exchange
membranes to grow small particles for
optical detection using standard
methods. Further, these methods allow
the system to separate condensation and
aerosol flow to enhance user mobility.
Moreover, the described methods use
inexpensive materials and require low
power for operation.
The prospective exclusive license will
be royalty bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR part 404. The
prospective exclusive license may be
granted unless, within thirty (30) days
from the date of this published notice,
the NIH Office of Technology Transfer
receives written evidence and argument
that establishes that the grant of the
contemplated license would not be
consistent with the requirements of 35
U.S.C. 209 and 37 CFR part 404.
Properly filed competing applications
for a license in the prospective field of
use that are filed in response to this
notice will be treated as objections to
the contemplated license. Comments
and objections submitted in response to
this notice will not be made available
for public inspection, and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Prospective Grant of Exclusive
License: Development of a ME–TARP
Based Immunotherapy
SUPPLEMENTARY INFORMATION:
BILLING CODE 4140–01–P
SUMMARY:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Dated: September 28, 2015.
Richard U. Rodriguez,
Acting Director, Office of Technology
Transfer, National Institutes of Health.
[FR Doc. 2015–24985 Filed 10–1–15; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00079
Fmt 4703
Sfmt 4703
National Institutes of Health
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
This is notice, in accordance
with 35 U.S.C. 209 and 37 CFR 404.7,
that the National Institutes of Health,
Department of Health and Human
Services, is contemplating the grant of
an exclusive patent license to practice
the inventions embodied in the
following U.S. Patents and Patent
Applications to PDS Biotechnology
Corporation (‘‘PDS’’) located in New
Brunswick, New Jersey, USA:
SUMMARY:
Intellectual Property
1. United States Provisional Patent
Application No. 60/476,467, filed June 5,
2003, entitled ‘‘Immunogenic Peptides
and Peptide Derivatives For The
Treatment of Prostate And Breast Cancer
Treatment’’ [HHS Reference No. E–116–
2003/0–US–01];
2. International Patent Application No. PCT/
US2004/17574 filed June 2, 2004 entitled
‘‘Immunogenic Peptides And Peptide
Derivatives For The Treatment of
Prostate And Breast Cancer Treatment’’
[HHS Reference No. E–116–2003/0–
PCT–02];
3. United States Patent No.7,541,035, issued
June 2, 2009, entitled ‘‘Immunogenic
Peptides And Peptide Derivatives For
The Treatment of Prostate And Breast
Cancer Treatment’’ [HHS Reference No.
E–116–2003/0–US–03];
4. United States Patent No. 8,043,623, issued
25 Oct 2011, entitled ‘‘Immunogenic
Peptides and Peptide Derivatives For
The Treatment of Prostate And Breast
Cancer Treatment’’ [HHS Reference No.
E–116–2003/0–US–04];
5. United States Provisional Patent
Application No. 61/915,948, filed
December 13, 2013, entitled ‘‘MultiEpitope TARP Peptide Vaccine and Uses
Thereof’’ [HHS Reference No. E–047–
2014/0–US–01];
6. International Patent Application No. PCT/
US2014/070144 filed December 12, 2014
entitled ‘‘Multi-Epitope TARP Peptide
Vaccine and Uses Thereof’’ [HHS
Reference No. E–047–2014/0–PCT–02];
and all continuation applications,
divisional applications and foreign
counterpart applications claiming
priority to the US provisional
application no. 61/915, 948.
The patent rights in these inventions
have been assigned to the government of
the United States of America.
The prospective exclusive license
territory may be worldwide and the
E:\FR\FM\02OCN1.SGM
02OCN1
]]>Agencies
[Federal Register Volume 80, Number 191 (Friday, October 2, 2015)]
[Notices]
[Pages 59797-59798]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-24982]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of a Start-up Exclusive Commercial License
Agreement: Development of MHC Class II Restricted T Cell Epitopes From
the Cancer Antigen, NY ESO-1, for the Treatment of Human Cancers
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. 209 and 37 CFR
part 404.7, that the National Institutes of Health, Department of
Health and Human Services, is contemplating the grant of an start-up
exclusive commercial license to Immunova Therapeutics, Inc., which is
located in Houston, Texas, to practice the inventions embodied in the
following patent applications and applications claiming priority to
these applications:
E-090-2000
1. U.S. Provisional Patent Application No. 61/179,004 filed January
28, 2000 entitled ``MHC Class II Restricted T Cell Epitopes from the
Cancer Antigen, NY ESO-1'' (HHS Ref No. E-090-2000/0-US-01);
2. U.S. Provisional Patent Application No. 60/237,107 filed
September 29, 2000 entitled ``HLA-DP Restricted CD4+ T Cell Epitopes
from the Cancer Antigen, NY ESO-1'' (HHS Ref No. E-227-2000/0-US-01
was combined with E-090-2000/0-US-01 at the PCT stage, creating the
E-090-2000/1 technology family and associated applications);
3. PCT Application No. PCT/US01/02765 filed January 26, 2001
entitled ``MHC Class II Restricted T Cell Epitopes from the Cancer
Antigen, NY ESO-1'' (HHS Ref No. E-090-2000/1-PCT-01);
4. Canadian Patent No. 2398743 issued June 23, 2015 entitled ``MHC
Class II Restricted T Cell Epitopes from the Cancer Antigen, NY ESO-
1'' (HHS Ref No. E-090-2000/1-CA-02);
5. Australian Patent No. 785151 issued January 18, 2007 entitled
``MHC Class II Restricted T Cell Epitopes from the Cancer Antigen,
NY ESO-1'' (HHS Ref No. E-090-2000/1-AU-03);
6. Japanese Patent No. 5588363 issued August 1, 2014 entitled ``MHC
Class II Restricted T Cell Epitopes from the Cancer Antigen, NY ESO-
1'' (HHS Ref No. E-090-2000/1-JP-12);
7. U.S. Patent No. 7,619,057 issued November 17, 2009 entitled ``MHC
Class II Restricted T Cell Epitopes from the Cancer Antigen, NY ESO-
1'' (HHS Ref No. E-090-2000/1-US-06);
8. U.S. Patent No. 8,754,046 issued June 17, 2014 entitled ``MHC
Class II Restricted T Cell Epitopes from the Cancer Antigen, NY ESO-
1'' (HHS Ref No. E-090-2000/1-US-07);
9. U.S. Patent Application No. 12/568,134 filed September 28, 2009
entitled ``MHC Class II Restricted T Cell Epitopes from the Cancer
Antigen, NY ESO-1'' (HHS Ref No. E-090-2000/1-US-013);
10. European Patent Application No. 10010354.8 filed January 26,
2001 entitled ``MHC Class II Restricted T Cell Epitopes from the
Cancer Antigen, NY ESO-1'' (HHS Ref No. E-090-2000/1-EP-10);
The patent rights in these inventions have been assigned to the
Government of the United States of America. The prospective start-up
exclusive commercial license territory may be worldwide and the field
of use may be limited to the use of the Licensed Patent Rights to
develop, manufacture, distribute, sell and use NY-ESO-1 based vaccines
and cell therapy products for the treatment of NY-ESO-1-positive
cancers.
DATES: Only written comments and/or applications for a license which
are received by the NIH Office of Technology Transfer on or before
October 19, 2015 will be considered.
ADDRESSES: Requests for copies of the patent applications, inquiries,
comments, and other materials relating to the contemplated exclusive
evaluation option license should be directed to: Sabarni K. Chatterjee,
Ph.D., M.B.A., Senior Licensing and Patenting Manager, NCI Technology
Transfer Center, 9609 Medical Center Drive, RM 1E530 MSC 9702,
Bethesda, MD 20892-9702 (for business mail), Rockville, MD 20850-9702;
Telephone: (240) 276-5530; Facsimile: (240) 276-5504; Email:
chatterjeesa@mail.nih.gov.
SUPPLEMENTARY INFORMATION: NY-ESO-1 is a known tumor antigen which is
expressed on a broad range of tumor types, including melanoma, breast,
bladder, ovarian, prostate, head and neck cancers, neuroblastoma, and
small cell lung cancer. The above-referenced inventions embody the
identification of a number of novel immunogenic peptide epitopes, and
analogs thereof, which are derived from the NY-ESO-1 tumor antigen.
Specifically, this technology describes novel MHC Class II restricted
epitopes of NY-ESO-1 which are recognized by CD4+ T cells. It also
embodies the identification of two additional immunogenic peptide
epitopes of NY-ESO-1. The latter two epitopes are presented by HLA-DP4,
a prevalent MHC Class II allele present in 43-70% of Caucasians. The
inventors also determined that the DP allele is highly associated with
the NY-ESO-1 antibody production. In addition, one of these epitopes
has dual HLA A2 and DP4 specificity, thereby it has the potential to
generate both CD4+ and CD8+ tumor specific T cells. These epitopes may
be of great value as prophylactic and/or therapeutic cancer vaccines or
cell therapy products for use against a number of common cancers.
The prospective start-up exclusive commercial license is being
considered under the small business initiative launched on October 1,
2011 and will comply with the terms and conditions of 35 U.S.C. 209 and
37 CFR part 404.7. The prospective start-up exclusive commercial
license may be granted unless within fifteen (15) days from the date of
this published notice, the NIH receives written evidence and argument
that establishes that the grant of the license would not be consistent
with the requirements of 35 U.S.C. 209 and 37 CFR part 404.7.
Any additional, properly filed, and complete applications for a
license in the field of use filed in response to this notice will be
treated as objections to the grant of the contemplated exclusive
commercial license. Comments and objections submitted to this notice
will not be made available for public inspection and, to the extent
permitted by law, will not be released under the Freedom of Information
Act, 5 U.S.C. 552.
[[Page 59798]]
Dated: September 28, 2015.
Richard U. Rodriguez,
Acting Director, Office of Technology Transfer, National Institutes of
Health.
[FR Doc. 2015-24982 Filed 10-1-15; 8:45 am]
BILLING CODE 4140-01-P
